Perhaps it's fitting that of the more than two dozen late-breaking clinical trials presented at this year's American College of Cardiology (ACC) meeting, it was a device trial—and an interventional device at that—that created the most buzz. No doubt the meeting planners recognized the high degree of interest the study would generate when they placed the EVEREST II trial in the first set of late-breakers—the only device study in the midst of several drug trial heavy-hitters covering a range of topics on the use of lipid- lowering and blood pressure medications in diabetics. But soon after the session was over, it was clear that the EVEREST II presentation—the first look at 12-month safety and efficacy outcomes from a randomized comparison of the MitraClip edge-to-edge percutaneous mitral valve repair system (developed by Evalve Inc., now part of Abbott Laboratories Inc.'s Abbott Vascular[See Deal]) versus surgical valve repair or replacement surgery—had stolen the show.
Conducted at over 40 sites in the US and Canada, the pivotal EVEREST II study enrolled 279 patients with significant mitral regurgitation (MR 3+/4+; 73% had degenerative MR and 27%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
